keyword
MENU ▼
Read by QxMD icon Read
search

Cardiorenal

keyword
https://www.readbyqxmd.com/read/29764920/right-heart-failure-unrecognized-cause-of-cardiorenal-syndrome
#1
Shweta Bansal, Anand Prasad, Stuart Linas
No abstract text is available yet for this article.
May 15, 2018: Journal of the American Society of Nephrology: JASN
https://www.readbyqxmd.com/read/29738821/discovery-and-development-of-sgc-stimulators-for-the-treatment-of-pulmonary-hypertension-and-rare-diseases
#2
REVIEW
Peter Sandner, Eva-Maria Becker-Pelster, Johannes Peter Stasch
The NO/sGC/cGMP signaling cascade plays a pivotal role in regulation of cardiovascular, cardiopulmonary and cardiorenal diseases and impairment of this cascade results in severe pathologies. Therefore, pharmacological interventions, targeting this pathway are promising strategies for treating a variety of diseases. Nitrates, supplementing NO and, PDE5 inhibitors preventing cGMP degradation, are used for angina pectoris treatment and the treatment of pulmonary arterial hypertension (PAH), respectively. More recently, a new class of drugs which directly stimulate the sGC enzyme and trigger NO-independent cGMP production was introduced and termed sGC stimulators...
May 5, 2018: Nitric Oxide: Biology and Chemistry
https://www.readbyqxmd.com/read/29735306/renoprotective-effects-of-sodium-glucose-cotransporter-2-inhibitors
#3
REVIEW
Hiddo J L Heerspink, Mikhail Kosiborod, Silvio E Inzucchi, David Z I Cherney
Over the past two years, our understanding of anti-hyperglycemic medications used to treat patients with type 2 diabetes (T2D) has fundamentally changed. Before the EMPA-REG OUTCOME trial, agents used to lower blood glucose were felt to prevent or delay the development of microvascular complications, but were not known to definitively reduce cardiovascular risk or mortality. Previous studies with then novel sodium-glucose cotransport-2 (SGLT2) inhibitors demonstrated improvements in several cardiovascular and renal risk factors, including HbA1c, blood pressure, weight, renal hyperfiltration, and albuminuria...
May 5, 2018: Kidney International
https://www.readbyqxmd.com/read/29710336/association-of-fibroblast-growth-factor-23-with-recurrent-cardiovascular-events-in-patients-after-an-acute-coronary-syndrome-a-secondary-analysis-of-a-randomized-clinical-trial
#4
Brian A Bergmark, Jacob A Udell, David A Morrow, Christopher P Cannon, Dylan L Steen, Petr Jarolim, Andrzej Budaj, Christian Hamm, Jianping Guo, KyungAh Im, Julia F Kuder, Eugene Braunwald, Marc S Sabatine, Michelle L O'Donoghue
Importance: Elevated fibroblast growth factor 23 (FGF-23) concentrations are associated with myocardial fibrosis and renin-angiotensin system upregulation, potentially providing prognostic information distinct from standard cardiovascular (CV) biomarkers. Objective: To evaluate the association of FGF-23 with recurrent CV events in patients after an acute coronary syndrome (ACS). Design, Setting, and Participants: C-terminal FGF-23 was measured in plasma samples using an established enzyme-linked immunosorbent assay system for 4947 patients within 30 days of ACS (median, 14 days) and with 1 additional CV risk factor in the Stabilization of Plaques Using Darapladib-Thrombolysis in Myocardial Infarction 52 (SOLID-TIMI 52) trial of the lipoprotein-associated phospholipase A2 inhibitor darapladib vs placebo performed from December 1, 2009, to April 24, 2014 (median follow-up, 2...
April 18, 2018: JAMA Cardiology
https://www.readbyqxmd.com/read/29701173/cyclical-cardiorenal-syndrome-in-late-stage-kidney-disease
#5
Benson Ku, Steven Fishbane
INTRODUCTION: In patients with late-stage chronic kidney disease (LS-CKD, estimated glomerular filtration rate (eGFR) < 30 mL/min) there is a high prevalence of congestive heart failure (CHF). We have observed a cyclical nature in the "cardiorenal syndrome" in LS-CKD, not previously described. The purpose of this article is to describe the syndrome and review its characteristics. MATERIALS AND METHODS: Patients enrolled in the Northwell Health Healthy Transitions in Late Stage Kidney Disease Program (HT) were followed, all with eGFR 0 - 30 mL/min...
April 27, 2018: Clinical Nephrology
https://www.readbyqxmd.com/read/29700563/what-s-new-in-cardiorenal-syndrome
#6
Michael Darmon, Miet Schetz
No abstract text is available yet for this article.
April 26, 2018: Intensive Care Medicine
https://www.readbyqxmd.com/read/29693019/biomarkers-in-cardiorenal-syndromes
#7
REVIEW
Shihui Fu, Shaopan Zhao, Ping Ye, Leiming Luo
There is a consensus that cardiorenal syndromes (CRS) are defined as the disorders of heart and kidney where acute or chronic dysfunction in one organ may induce acute or chronic dysfunction in another. Patients with CRS have increased hospitalization and mortality rates, and thus their identification is of great implication. Biomarkers are not only predictive in heart failure or renal diseases, but also useful in identifying cardiac dysfunction in renal diseases and renal injury in heart failure. Thus, they may be applied in order to identify patients with CRS and even assess prognosis and guide therapy in these patients...
2018: BioMed Research International
https://www.readbyqxmd.com/read/29686015/blood-pressure-related-risk-among-users-versus-nonusers-of-antihypertensives-a-population-based-cohort-in-korea
#8
Hae Hyuk Jung, Ji In Park, Jin Seon Jeong
There have been few studies comparing blood pressure (BP)-related outcomes between users and nonusers of antihypertensive drugs. We constructed a population-based cohort of 492 540 Koreans aged 40 to 79 years, who had no preexisting cardiorenal diseases, from the National Health Insurance Service-Health Screening database. The primary composite outcome was death (or critical care unit admission) from cardiorenal causes, revascularization for myocardial infarction or stroke, and new-onset end-stage renal disease...
April 23, 2018: Hypertension
https://www.readbyqxmd.com/read/29671622/changes-in-kidney-tissue-and-effects-of-erythropoietin-after-acute-heart-failure
#9
A Güven Bağla, M Içkin Gülen, F Ercan, F Aşgün, E Ercan, C Bakar
Impairment of cardiac function causes renal damage. Renal failure after heart failure is attributed to hemodynamic derangement including reduced renal perfusion and increased venous pressure. One mechanism involves apoptosis and is defined as cardiorenal syndrome type 1. Erythropoietin (EPO) is a cytokine that induces erythropoiesis under hypoxic conditions. Hypoxia inducible factor 1 alpha (HIF-1α) plays a regulatory role in cellular response to hypoxia. Protective effects of EPO on heart, kidney and nervous system are unrelated to red blood cell production...
April 19, 2018: Biotechnic & Histochemistry: Official Publication of the Biological Stain Commission
https://www.readbyqxmd.com/read/29627841/preeclampsia-as-a-form-of-type-5-cardiorenal-syndrome-an-underrecognized-entity-in-women-s-cardiovascular-health
#10
Janani Rangaswami, Mario Naranjo, Peter A McCullough
BACKGROUND: Preeclampsia is a multisystem vascular disorder of pregnancy that remains a leading cause of maternal and fetal morbidity and mortality. Preeclampsia remains an underrecognized risk factor for future cardiovascular and kidney disease in women and represents the confluence of preexisting vascular risk factors with superimposed endothelial injury from placental mediated anti-angiogenic factors. SUMMARY: This review highlights the close relationship between preeclampsia and future cardiovascular and kidney disease...
2018: Cardiorenal Medicine
https://www.readbyqxmd.com/read/29627837/combination-of-mean-platelet-volume-platelet-count-ratio-and-the-apache-ii-score-better-predicts-the-short-term-outcome-in-patients-with-acute-kidney-injury-receiving-continuous-renal-replacement-therapy
#11
Junhui Li, Yingchuan Li, Xiaohua Sheng, Feng Wang, Dongsheng Cheng, Guihua Jian, Yongguang Li, Liang Feng, Niansong Wang
BACKGROUND/AIMS: Both the Acute physiology and Chronic Health Evaluation (APACHE II) score and mean platelet volume/platelet count Ratio (MPR) can independently predict adverse outcomes in critically ill patients. This study was aimed to investigate whether the combination of them could have a better performance in predicting prognosis of patients with acute kidney injury (AKI) who received continuous renal replacement therapy (CRRT). METHODS: Two hundred twenty-three patients with AKI who underwent CRRT between January 2009 and December 2014 in a Chinese university hospital were enrolled...
March 29, 2018: Kidney & Blood Pressure Research
https://www.readbyqxmd.com/read/29623594/combination-treatment-of-sglt2-inhibitors-and-glp-1-receptor-agonists-symbiotic-effects-on-metabolism-and-cardiorenal-risk
#12
REVIEW
Edison Goncalves, David S H Bell
INTRODUCTION: When treating type 2 diabetes, drugs that cause hypoglycemia and weight gain should, if possible, be avoided. In addition, due to the increased incidence and prevalence of cardiovascular disease, cardiac events and heart failure, as well as the accelerated renal decompensation that may occur with type 2 diabetes, hypoglycemic agents that have the potential to lower cardiac and renal risk should be utilized as early as possible in the course of the disease. METHODS: This is a literature review of the efficacy of combined treatment with a glucagon-like peptide 1 (GLP-1) agonist and a sodium glucose cotransporter-2 (SGLT2) inhibitor in lowering glycated hemoglobin (HbA1c) level, cardiac risk, cardiac events and renal decompensation...
April 5, 2018: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/29617002/the-role-of-dendritic-and-endothelial-cells-in-cardiorenal-syndrome
#13
Grazia Maria Virzì, Jun Zhang, Federico Nalesso, Claudio Ronco, Peter A McCullough
BACKGROUNDS: Dendritic cells (DCs) are antigen-presenting cells that play a central role in innate and adaptive immune responses; however, the cross talk between cardiac and renal DCs in cardiorenal syndrome (CRS) has not yet been fully elucidated. In this setting, endothelial cells (ECs) also contribute to immune responses. SUMMARY: DC and EC activation and dysfunction have a central role in the pathogenesis of CRS. Regarding immune responses in CRS, it is unknown whether ECs may serve as antigen-presenting cells or act synergistically with DCs to actively participate in innate and adaptive immune responses...
January 22, 2018: Cardiorenal Medicine
https://www.readbyqxmd.com/read/29602175/effect-of-anemia-on-prognosis-in-patients-on-extracorporeal-membrane-oxygenation
#14
Chang-Chyi Jenq, Feng-Chun Tsai, Tsung-Yu Tsai, Sue-Yun Hsieh, Yi-Wen Lai, Ya-Chung Tian, Ming-Yang Chang, Chan-Yu Lin, Ji-Tseng Fang, Chih-Wei Yang, Yung-Chang Chen
Anemia is a component of the pathological triangle in cardiorenal anemia syndrome and is a risk factor for mortality in acute respiratory distress syndrome. This study assessed the predictive value of anemia for outcomes in critically ill patients receiving extracorporeal membrane oxygenation (ECMO) support. This retrospective study analyzed patients who received ECMO support at the cardiovascular surgery intensive care unit in the study institute between July 2003 and March 2012. Patient data, such as demographic information, etiologies of ECMO implementation, clinical parameters, and in-hospital and 6-month mortality rates, were statistically analyzed...
March 30, 2018: Artificial Organs
https://www.readbyqxmd.com/read/29600538/sb-216763-a-gsk-3%C3%AE-inhibitor-protects-against-aldosterone-induced-cardiac-and-renal-injury-by-activating-autophagy
#15
Yi-De Zhang, Xiao-Jun Ding, Hou-Yong Dai, Wei-Sheng Peng, Nai-Feng Guo, Yuan Zhang, Qiao-Ling Zhou, Xiao-Lan Chen
Cardiovascular and renal inflammation induced by Aldosterone (Aldo) plays a pivotal role in the pathogenesis of hypertension and renal fibrosis. GSK-3β contributes to inflammatory cardiovascular and renal diseases, but its role in Aldo-induced hypertension, and renal damage is not clear. In the present study, rats were treated with Aldo combined with SB-216763 (a GSK-3β inhibitor) for 4 weeks. Hemodynamic, cardiac, and renal parameters were assayed at the indicated time. Here we found that rats treated with Aldo presented cardiac and renal hypertrophy and dysfunction...
March 30, 2018: Journal of Cellular Biochemistry
https://www.readbyqxmd.com/read/29599092/cardiorenal-syndrome-as-predictor-of-in-hospital-mortality-in-st-segment-elevation-myocardial-infarction
#16
Ailed Elena Rodríguez-Jiménez, Tessa Negrín-Valdés, Hugo Cruz-Inerarity, Pedro Javier Machural-de la Torre
INTRODUCTION: Cardiorenal syndrome includes numerous conditions affecting the heart and kidney, and is a strong predictor of cardiovascular mortality. METHOD: An analysis was performed on 157 consecutive patients admitted to the Coronary Care Unit of the Camilo Cienfuegos Hospital due to an ST-segment elevation myocardial infarction and heart failure, from January 2013 to December 2016. An analysis was made of the presence of cardiorenal syndrome and its relationship with epidemiological, clinical, and analytical variables, as well as complementary explorations...
March 26, 2018: Clínica e Investigación en Arteriosclerosis
https://www.readbyqxmd.com/read/29587582/spironolactone-to-increase-natriuresis-in-congestive-heart-failure-with-cardiorenal-syndrome
#17
Frederik H Verbrugge, Pieter Martens, Koen Ameloot, Veerle Haemels, Joris Penders, Matthias Dupont, W H Wilson Tang, Walter Droogné, Wilfried Mullens
BACKGROUND: Signs and symptoms of volume overload are the most frequent reason for hospital admission in acute heart failure (AHF). Diuretics are mainstay treatment, but their optimal type and dose regimen remain unclear, especially in patients with cardiorenal syndrome. METHODS: This prospective study aimed to include 80 AHF patients with volume overload and cardiorenal syndrome. Through a 2 × 2 factorial design, patients were randomised towards (1) combinational treatment with acetazolamide and low-dose loop diuretics versus high-dose loop diuretics; and (2) open-label oral spironolactone 25 mg OD given upfront versus at discharge...
March 27, 2018: Acta Cardiologica
https://www.readbyqxmd.com/read/29566363/cardiac-specific-overexpression-of-silent-information-regulator-1-protects-against-heart-and-kidney-deterioration-in-cardiorenal-syndrome-via-inhibition-of-endoplasmic-reticulum-stress
#18
Dong Huang, Mei-Ling Yan, Kan-Kai Chen, Rong Sun, Zhi-Feng Dong, Peng-Long Wu, Shuai Li, Guang-Shuo Zhu, Shi-Xin Ma, Ye-Sheng Pan, Jing-Wei Pan, Wei Zhu, Jun Xu, Meng Wei, Jing-Bo Li
BACKGROUND/AIMS: Increased endoplasmic reticulum (ER) stress contributes to development of cardiorenal syndrome (CRS), and Silent Information Regulator 1 (SIRT1), a class III histone deacetylase, may have protective effects on heart and renal disease, by reducing ER stress. We aimed to determine if SIRT1 alleviates CRS through ER stress reduction. METHODS: Wild type mice (n=37), mice with cardiac-specific SIRT1 knockout (n=29), or overexpression (n=29), and corresponding controls, were randomized into four groups: sham MI (myocardial infarction) +sham STNx (subtotal nephrectomy); MI+sham STNx; sham MI+STNx; and MI+STNx...
March 21, 2018: Cellular Physiology and Biochemistry
https://www.readbyqxmd.com/read/29558902/emergency-transcatheter-aortic-valve-replacement-for-a-patient-with-decompensated-severe-aortic-stenosis-accompanied-by-cardiorenal-syndrome-a-case-report
#19
Hongju Kim, Jung-Hee Lee
BACKGROUND: Severe aortic stenosis (AS) may lead to acute decompensated heart failure resistant to medical treatment. Here, we report a successful emergent transcatheter aortic valve replacement (TAVR) in a patient presenting with decompensated severe AS accompanied by cardiorenal syndrome. CASE PRESENTATION: A 82-year-old man presented at our emergency department with aggravated dyspnea. His chest X-ray showed bilateral pulmonary edema, and laboratory examination revealed acute kidney injury...
March 20, 2018: BMC Cardiovascular Disorders
https://www.readbyqxmd.com/read/29557615/-tolvaptan-in-a-pediatric-cardiorenal-syndrome-what-is-its-role
#20
M Angeles Tejero Hernández, Elena García Martínez, M José Arroyo Marin, Elena Gómez Guzmán
The cardiorenal syndrome has been defined as a situation in which therapy to relieve congestive symptoms of heart failure is limited by a decreased renal function. The resistance to conventional diuretic treatment makes difficult managing these patients. Tolvaptan, a selective vasopressin-2 receptor antagonist, has been used successfully in adults with this pathology but the experience with children is very limited. A five-year-old girl with renal failure waiting for a heart transplant is presented. Tolvaptan (0...
April 1, 2018: Archivos Argentinos de Pediatría
keyword
keyword
4190
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"